AR121289A1 - Formas cristalinas del compuesto ftalazinona - Google Patents

Formas cristalinas del compuesto ftalazinona

Info

Publication number
AR121289A1
AR121289A1 ARP210100326A ARP210100326A AR121289A1 AR 121289 A1 AR121289 A1 AR 121289A1 AR P210100326 A ARP210100326 A AR P210100326A AR P210100326 A ARP210100326 A AR P210100326A AR 121289 A1 AR121289 A1 AR 121289A1
Authority
AR
Argentina
Prior art keywords
compound
crystalline forms
phthalacinone
crystalline
phthalazin
Prior art date
Application number
ARP210100326A
Other languages
English (en)
Inventor
Kunhee Lee
Seoktaek Lee
Keuncheol Ryu
Hanna Seo
Hyeran Yang
Wonje Seong
Jinyoung Yoon
Original Assignee
Idience Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idience Co Ltd filed Critical Idience Co Ltd
Publication of AR121289A1 publication Critical patent/AR121289A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente memoria proporciona las formas cristalinas de clorhidrato 4-[3-(3-[(ciclopropilamino)metil]azetidina-1-carbonil)-4-fluorobenzil]ftalazin-1(2H)-ona, sus métodos de preparación y las composiciones farmacéuticas que lo comprenden. Reivindicación 1: Una forma cristalina de un compuesto de la fórmula (1), caracterizada por exhibir un patrón de difracción de rayos X de polvos (XRPD) que comprende picos en valores 2q ± 0,2º de 13,7º, 15,9º y 24,1º.
ARP210100326A 2020-04-21 2021-02-09 Formas cristalinas del compuesto ftalazinona AR121289A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063013276P 2020-04-21 2020-04-21

Publications (1)

Publication Number Publication Date
AR121289A1 true AR121289A1 (es) 2022-05-04

Family

ID=78081129

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100326A AR121289A1 (es) 2020-04-21 2021-02-09 Formas cristalinas del compuesto ftalazinona

Country Status (13)

Country Link
US (2) US11390608B2 (es)
EP (1) EP4139297A4 (es)
JP (1) JP2023537550A (es)
KR (1) KR20230004723A (es)
CN (1) CN115702151A (es)
AR (1) AR121289A1 (es)
AU (1) AU2020444056A1 (es)
BR (1) BR112022021321A2 (es)
CA (1) CA3176219A1 (es)
IL (1) IL297464A (es)
MX (1) MX2022013304A (es)
TW (1) TW202140456A (es)
WO (1) WO2021214503A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL314334A (en) * 2022-01-25 2024-09-01 Idience Co Ltd A pharmaceutical preparation that includes a phthalazinone derivative for co-administration with an anti-cancer drug

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ525138A (en) 2000-10-30 2004-03-26 Kudos Pharm Ltd Phthalazinone derivatives for use as PARP inhibitors
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
CA2482806A1 (en) 2002-04-30 2003-11-13 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
CA2652167A1 (en) 2006-05-31 2007-12-06 Philip Jones Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
MY165570A (en) 2006-12-28 2018-04-05 Abbvie Inc Inhibitors of poly (adp-ribose) polymerase
US8268827B2 (en) 2007-11-15 2012-09-18 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa. Pyridazinone derivatives as PARP inhibitors
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
JP2013532683A (ja) 2010-07-27 2013-08-19 カディラ ヘルスケア リミティド ポリ（ａｄｐリボース）ポリメラーゼ−１阻害剤としての、置換４−（４−フルオロ−３−（ピペラジン−１−カルボニル）ベンジル）フタラジン−１（２ｈ）−オン誘導体
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372706A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372698A (zh) 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
JP5699223B2 (ja) * 2010-12-02 2015-04-08 シャンハイ デュァ ノボ ファルマテック カンパニー リミテッド 複素環誘導体、その合成法および医療用途
CN102485721B (zh) 2010-12-03 2015-12-09 曹亚 取代的2,3-二氮杂萘酮化合物及其用途
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
KR101670126B1 (ko) 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
KR20170037116A (ko) * 2015-09-25 2017-04-04 일동제약(주) 플루오로기가 치환된 프탈라지논 유도체 및 그 제조방법
US20190177281A1 (en) * 2016-05-03 2019-06-13 Sromovasam THIRUMALAI RAJAN Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl] [(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino] methyl-2-methoxybenzoic acid and its polymorphs thereof

Also Published As

Publication number Publication date
IL297464A (en) 2022-12-01
US11390608B2 (en) 2022-07-19
CA3176219A1 (en) 2021-10-28
AU2020444056A1 (en) 2022-11-17
BR112022021321A2 (pt) 2022-12-20
US20210323945A1 (en) 2021-10-21
EP4139297A4 (en) 2024-05-22
MX2022013304A (es) 2022-12-15
KR20230004723A (ko) 2023-01-06
US20220372020A1 (en) 2022-11-24
EP4139297A1 (en) 2023-03-01
US11691964B2 (en) 2023-07-04
WO2021214503A1 (en) 2021-10-28
JP2023537550A (ja) 2023-09-04
CN115702151A (zh) 2023-02-14
TW202140456A (zh) 2021-11-01

Similar Documents

Publication Publication Date Title
JOP20210001A1 (ar) مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
PH12020500125A1 (en) 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JOP20190182A1 (ar) أسيتاميد n-] 4-فلور-5-]] (4s,2s)-2-ميثيل-4-](5-ميثيل-1،2،4-اوكسادايزول-3-يل)ميثوكسي[-1-بيبيرديل[ميثيل[ ثيازول-2-يل[ كمثبط oga
MY197260A (en) Fungicidal oxadiazoles
MX2021005295A (es) Tolilos sustituidos como fungidas.
CY1123025T1 (el) Αναστολεις βρωμοεπικρατειας
BR112022008919A2 (pt) Composto e método para tratamento de distúrbios psiquiátrico ou neurológico
NZ752728A (en) Oxysterols and methods of use thereof
PH12021551167A1 (en) New heterocyclic compounds
MX2009012418A (es) Derivados de quinazolin-oxima como inhibidores de hsp90.
NZ752732A (en) Oxysterols and methods of use thereof
JP2018511587A5 (es)
MY139243A (en) Prodrugs of piperazine and substituted piperidine antiviral agents.
BRPI0804994A2 (pt) forma cristalina vi de agomelatina, um processo para a sua preparação e composições farmacêuticas contendo-a
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
NO20060949L (no) yd-krystallinsk form avivabradin-hydroklorid, fremgangsmate for dens frem5l1lling 0g farmasoytiske sammensetninger inneholdende den
PE20140171A1 (es) Pirazoles fungicidas y sus mezclas
NO20064588L (no) Delta d-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende den
NO20092279L (no) Makrocyklisk factor VIIa inhibitorer anvendbare som antikoagulanter
MX2020006799A (es) Derivados de oxi-fluoropiperidina como inhibidor de cinasa.
AR121289A1 (es) Formas cristalinas del compuesto ftalazinona
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
NZ734972A (en) Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
MX2024009925A (es) Composiciones y metodos para tratar trastornos del snc.